More than two dozen Maine hospitals were identified Wednesday as having received products from a Massachusetts pharmacy implicated in a recent outbreak of fungal meningitis.

The federal government’s expanded list names more than 30 health organizations in Maine, including Central Maine and St. Mary’s Regional medical centers in Lewiston.

The Food and Drug Administration list includes medical practices in each state that received products since May from the New England Compounding Center, the Framingham, Mass., pharmacy at the center of the multi-state outbreak.

Other drugs made by the pharmacy have not been linked to illnesses, but the FDA has recommended that patients who received products from the company be notified of the fact.

According to Randall Dustin, communications director at CMMC, that hospital has determined that it has not used the product identified as contaminated. Hospital officials are now compiling a list of patients who received other products from the Massachusetts pharmacy, Dustin said. He expects letters will go out to those patients by the end of the week.

The injectable steroid at the center of the outbreak was not used at all in Maine, health officials have said. Nonetheless, they are monitoring 74 Maine residents who were treated in New Hampshire with injections linked to the outbreak, according to the Maine Center for Disease Control and Prevention.

The outbreak has caused more than 300 illnesses and 24 deaths nationally, health officials said. The expanded list can be found at http://www.fda.gov/downloads/Drugs/DrugSafety/FungalMeningitis/UCM325467.pdf


Only subscribers are eligible to post comments. Please subscribe or to participate in the conversation. Here’s why.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.